Connect with us

Government

10,000 Illegal Immigrants To Arrive Daily At US Border, Warns Mexican President

10,000 Illegal Immigrants To Arrive Daily At US Border, Warns Mexican President

Authored by Naveen Athrappully via The Epoch Times (emphasis…

Published

on

10,000 Illegal Immigrants To Arrive Daily At US Border, Warns Mexican President

Authored by Naveen Athrappully via The Epoch Times (emphasis ours),

Mexican President Andrés Manuel López Obrador has warned that the United States will soon see about 10,000 illegal immigrants per day arrive at its border with Mexico.

Hundreds of illegal immigrants line up outside of the Jacob K. Javits Federal Building in New York City on June 6, 2023. (David Dee Delgado/Getty Images)

Such a large number of illegal immigrants are reaching Mexico’s northern border with the United States partly due to abount 6,000 illegal immigrants crossing from Guatemala into Mexico every day for the past week, President Obrador said on Oct. 2, according to The Associated Press. The Mexican president criticized U.S. sanctions on nations such as Cuba and Venezuela, two nationalities that make up a significant portion of the illegal immigrant flow.

On Sept. 29, President Obrador called on the United States to “remove blockades and stop harassing independent and free countries.” There should be “an integrated plan for cooperation so the Venezuelans, Cubans, Nicaraguans, Ecuadorans, Guatemalans, and Hondurans wouldn’t be forced to emigrate,” he said.

He also criticized the United States' use of funds to support Ukraine in its war against Russia and argued that some of the money sent to Ukraine should be spent on economic development in Latin America.

The Mexican president's comments come as the country has done little to prevent migrants from getting onto trains headed to the U.S. border.

Moreover, Mexico currently runs a government program that sends buses for migrants in the southern region, transporting thousands of these people to its northern border with the United States.

In the city of Juchitán in Oaxaca state, Mexico, some migrants told Reuters that they were planning on entering the United States using the U.S. government’s CBP One app and then requesting asylum.

CBP One was launched in 2020. In January this year, the Biden administration announced new legal pathways for asylum seekers and other illegal immigrants through the app. Illegal immigrants can now schedule appointments at ports of entry or manned entry points at America’s border with Mexico through CBP One.

According to data from the U.S. Customs and Border Protection (CBP), there were 232,972 encounters with illegal immigrants at the southwest land border in August, up from 183,494 in July.

Overall, 2.2 million illegal immigrant encounters have been recorded for fiscal year 2023 until August, on pace to meet or exceed the 2.37 million encounters in fiscal year 2022. In the 2021 fiscal year, the number of encounters was lower at 1.73 million. And in fiscal year 2020, there were only 458,088 encounters.

Illegal Influx Into America

The influx of illegal immigrants has alarmed officials in U.S. border communities. Late last month, the Democrat Mayor of El Paso, Texas, said that the illegal aliens were straining the region’s resources.

“The city of El Paso only has so many resources, and we have come to ... a breaking point right now,” El Paso Mayor Oscar Leeser said during a news conference, according to Reuters. More than 2,000 people were seeking asylum every day in El Paso.

Illegal immigrants come through the US–Mexico border through a remote portion of the Arizona desert on Sept. 1, 2023. (Associated Press/Screenshot via The Epoch Times)

In a Sept. 21 post on X, Republican Texas Gov. Greg Abbott denounced the Biden administration for the migrant crisis facing the United States.

I officially declared an invasion at our border because of Biden's policies. We deployed the Texas National Guard, DPS [and] local law enforcement. We are building a border wall, razor wire [and] marine barriers. We are also repelling migrants,” he said.

In a recent interview with MSNBC, Rep. Henry Cuellar (D-Texas) claimed that the government isn't deporting enough illegal immigrants who are entering the country and pushed for adopting a stronger stance on the issue against countries such as Mexico.

“Let’s say we get 10,000 people a day, we’re deporting about 1,000 a day. So, you can see the numbers don’t add up there,” he said. “You’ve got to have repercussions at the border, you’ve got to have the other countries, Mexico and the other countries, do more.

“This is very important, 2015, 2019, [illegal immigrant] numbers went down; why? Under Obama and under Trump, why? Because we were able to get the Mexicans to do a lot more and stop them at the southern border with Guatemala. And that’s what history shows. Play defense on their 20-yard line and have real repercussions, and I mean deport people. Otherwise, they’re going to keep coming to the [United States].”

It’s not just at the Mexican border that the United States is facing an influx of illegal immigrants. The situation is getting worse at the northern border with Canada as well.

In the northeastern Swanton Sector, illegal immigrant apprehensions this year alone have exceeded the total of the past decade.

“Over 6,100 apprehensions from 76 different countries in just 11 months, surpassing the last 10 years combined,” Swanton Sector Chief Patrol Agent Robert Garcia said in a Sept. 6 post on X.

“Swanton Sector Agents are resolute and determined to hold the line across our 295 miles of border in northeastern New York, Vermont, [and] New Hampshire.”

In fiscal year 2022, Swanton Sector saw 1,000 apprehensions, up from 365 in fiscal year 2021.

The Associated Press contributed to this report.

Tyler Durden Fri, 10/06/2023 - 14:45

Read More

Continue Reading

Government

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…

Published

on

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

Trending